FIGURE 1A AND FIGURE 1B




FIGURE 1C




FIGURE 2A




FIGURE 2B




FIGURE 2C



Phase Contrast Image
Fluorescent image
Uninfected cells
Virus control - Fusion
mAb4G2 - No Fusion
mAb9F12 - Fusion

FIGURE 2D





100
90
80
70
60
50
40
30
20
10
0
% of Protection
-12
-11
-10
-9
-8
-7
-6
-5
-4
9F12 log[M]

FIGURE 3A AND FIGURE 3B



(A)



(B)

FIGURE 4A



WT
K305E
K307Q
K310E
P384A
G330D
100
80
60
40
20
0
10^1 10^2 10^3 10^4 10^5
Neg Ctrl
Pos Ctrl
9F12

FIGURE 4B



DE loop
BC loop
G330
K307
K305
NTR
K310
A
B
E
FG loop
C
D
AB loop
G
F

FIGURE 5



mouse 1
mouse 2
mouse 3
mouse 4
mouse 5
mouse 6
mouse 7
mouse 8
Naive mouse
OD 405 nm
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
2
4
6
8
10
Day after infection

FIGURE 6A




FIGURE 6B




FIGURE 6C




FIGURE 7




FIGURE 8




Comparison of virus binding capacity of 9F12 against standard anti- dengue monoclonal antibodies
OD450nm
1.2
1
0.8
0.6
0.4
0.2
0
D1
D2
D2TSVO1
D3
D4
4G2
9F12
3H5

FIGURE 9A







FIGURE 9B






FIGURE 9C

